ZNTL logo

ZNTL Zentalis Pharmaceuticals, Inc.

NASDAQ · Biotechnology · Healthcare

$1.70
+0.02 (+1.19%)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The …

Market Cap: $167.05Mwww.zentalis.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
50
1 mentions
—
60d
50
3 mentions
—
90d
56
7 mentions
—
news: 7

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 3Sell 0Strong Sell 0
Avg price target$7.25+326.5%
Low $5Median $7High $10
Current Consensus

Revenue

$0.00
$0.00$13.52M$27.04M$40.56M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-1.82
$-1.98–$-1.67
6 analysts
FY2026
$-1.81
$-1.96–$-1.70
8 analysts
FY2027
$-1.66
$-1.81–$-1.23
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Julia Marie Eastland
Sector
Healthcare
Industry
Biotechnology
Employees
106
Beta
1.93
Country
US
Piotroski score
0 / 9 (Weak)
Altman Z-score
-6.00
www.zentalis.com